瑞银指出，诺诚健华第三季业绩超预期，亏损按年大幅缩小87.5%至1,360万元人民币，大幅优于市场预期的亏损约1.55亿元人民币。浦银国际则指出，上调港股目标价至9.2港元，维持“买入”评级；上调A股目标价至14.5元，下调A股评级至“持有”，因短期内A股股价已处于合理估值区间。Innocare (09969) has fallen over 7%, as of the time of writing, down 6.14%, priced at 7.03 HKD, with a transaction volume of 25.496 million HKD.
According to Zhitong Finance APP, Innocare (09969) has fallen over 7%, as of the time of writing, down 6.14%, priced at 7.03 HKD, with a transaction volume of 25.496 million HKD.
On the news front, Innocare previously announced its performance for the first three quarters ending September this year. According to China’s accounting standards, the revenue was 0.698 billion RMB, a year-on-year increase of 29.8%; the loss narrowed to 0.275 billion RMB, compared to a loss of 0.531 billion RMB in the same period last year. Benefiting from the strong growth of Ocriplasmin, management has raised the annual sales guidance for Ocriplasmin to ≥45% year-on-year growth, corresponding to 0.973 billion RMB.
UBS Group pointed out that Innocare's third-quarter performance exceeded expectations, with the loss significantly narrowed by 87.5% to 13.6 million RMB, much better than the market's expected loss of approximately 0.155 billion RMB. Purui International has raised the target price for HK stocks to 9.2 HKD, maintaining a "buy" rating; the target price for A-shares has been raised to 14.5 RMB, while the rating for A-shares has been lowered to "hold" due to the current reasonable valuation range of A-share prices.
